9th edition of SPNS Conference takes off today in Riyadh

Riyadh, Saudi Arabia: The 9th edition of the Saudi Pediatric Neurology Society (SPNS) Conference and Workshops takes off today in Riyadh, Saudi Arabia, the leading event organised by Maarefah Management, and featuring cutting-edge discussions and insights into various pediatric neurology topics. With participation of top healthcare officials, dignitaries, industry leaders, speakers, panellists', analysts and experts.
Prof. Fahad Al Bashiri, President SPNS, professor and consultant Pediatric Neurologist at the College of Medicine, King Saud University, will be sharing pivotal insights about the importance of vitamin 'D' in children's health and the recommended dose in children with epilepsy. Prof. Fahad Al Bashiri, said: 'Vitamin D plays a crucial role in maintaining bone health, muscle strength, immune function, and neurotransmission in the central nervous system in healthy children, patients with epilepsy are at high risk of developing vitamin D deficiency due to antiseizure medications (ASMs), leading to impaired bone quality and increased risk of fractures'.
'For children with epilepsy, there is a lack of conclusive evidence to recommend a specific maintenance dose Vitamin 'D'. In trial was approved by the institutional review board at King Saud University, correcting vitamin D deficiency status led to an increased number of seizure-free children, the treatment of 2.6 children with vitamin D deficiency was needed to increase the chances of being seizure-free, Vitamin 'D'treatment for adults with epilepsy lead to a reduction of seizure frequency by 30% in the treatment group compared to the control group, A pilot study in adults showed a significant 40%seizure reduction post-correction of vitD deficiency Hollo'. Added Prof. Fahad Al Bashiri.
This year's conference promises an enriching programme featuring cutting-edge discussions and insights into various pediatric neurology topics, including: Neonatal Neurology. Spinal Muscular Atrophy (SMA). Neuro inflammatory Disorders. Neuromuscular Diseases. Brain and Spinal Injuries and Infections. Epilepsy – Brain and Spinal Tumors. Cerebrovascular Disease. Autism. Movement Disorders. Metabolic and Genetic Disorders.
Prof. Mohammad Jan, Professor and Consultant of Pediatric Neurology and Clinical Neurophysiology Department of Paediatrics, Faculty of Medicine, King AbdulAziz University, KSA, commented, : Known consequence of primary or metastatic brain tumours, presenting manifestation in 13–24% of children, the only clinical manifestation in 7%, seizure control often aligns with tumour growth can improve with tumour treatment. Brain tumors are the second most common cancer types in children, overall annual incidence 7/100,000 population'.
Dr. Raidah Al-Baradie, Consultant Pediatric Neurology/Epilepsy, King Fahd specialist Hospital- Dammam: 'Epilepsy affects 50-70 million people worldwide, and nearly 1 % population will have epilepsy during lifetime, patients have recurrent unprovoked seizures which are clinical manifestation of abnormal neuronal discharges. Increased drugs options have not led to better outcomes, patients endure recurrent seizures before the 'right' drug is found, and there is a need to predict response to specific drugs for individual patients'.
'More than 30 new ASM approved in the past 30 years, No change in overall seizure freedom rate or tolerability, and one third of patients drug resistant, failure of the first drug is the strongest predictor of long term outcome, Choosing ASMs remains largely trial & error for individual patients, Machine learning model may serve as clinical decision support tool in drug selection, and prospective evaluation is needed' Dr. Raidah Al-Baradie, concluded.
For more information about The 9th edition of the Saudi Pediatric Neurology Society (SPNS) Conference, please visit: https://spnsociety.org.sa/2024-9th-annual-spns/

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Zawya

13-06-2025

• Zawya

Charting a value-driven healthcare future: BD Saudi Arabia's GM on local impact, innovation, and Vision 2030

In a candid conversation with Saudi Gazette, Omar Malabarey, newly appointed Country General Manager for Becton Dickinson in Saudi Arabia, shares his vision for the company's role in the Kingdom's fast-evolving healthcare sector. With decades of experience across public and private healthcare, Malabarey discusses BD's commitment to local talent development, digital transformation, and strategic partnerships aligned with Vision 2030. Q: Congratulations on your appointment as General Manager of BD in Saudi Arabia. Can you share your journey leading to this role and what it means to you? A: My journey in healthcare has been both dynamic and fulfilling. I graduated in Radiological Sciences from the University of Wales (UK)and began my career as a radiology technologist at a Military hospital in Riyadh, Saudi Arabia. Following a decade in public healthcare, I transitioned to the corporate sector, where I held several senior leadership roles in digital health services. My journey then took me to the Ministry of Investment (formerly SAGIA), where I was the managing director for healthcare investment and promotion efforts responsible of medical devices , medical services , digital health and pharmaceutical investments . Before joining BD, I held the role of Chief commercial officer (CCO)at the National Unified Procurement Company) NUPCO. Stepping into this role at BD is a natural continuation of my mission to enhance the healthcare ecosystem system in KSA. BD has a legacy of innovation in medical technology, and I am honoured to lead its efforts in Saudi Arabia to drive impactful healthcare transformation. Q: What are your immediate priorities as you take on this role? A: My priorities span both internal and external objectives. Internally, I am focused on fostering a strong, collaborative workplace culture. A key priority is to establish BD as an employer of choice in Saudi Arabia, attracting and retaining top local talent while ensuring alignment with the Kingdom's Saudization initiatives. Externally, my goal is to strengthen BD's presence and visibility in the Saudi market. While BD products are widely recognized, our corporate brand needs greater prominence among healthcare stakeholders. I want to position BD as not just a provider of high-quality medical technology but also as a key partner in Saudi Arabia's Vision 2030 and the Health Sector Transformation Program. Our focus is on value-driven healthcare—delivering not just products but comprehensive solutions, education, and best practices that enhance patient outcomes. A strong part of my role will be pursue rolling out our Signature Programmes™ in Saudi Arabia, which focus on three critical areas: Patient Safety, Healthcare Worker Safety, and Healthcare Efficiency. These initiatives are designed to enhance infection control, improve hospital workflows, and to help ensure the safety of both patients and medical professionals. Through these programmes, BD is helping hospitals and healthcare institutions in Saudi Arabia implement best practices that drive meaningful improvements in patient outcomes and operational efficiencies. Q: Why is Saudi Arabia a strategic market for BD, and how does the company align with Vision 2030? A: Saudi Arabia is undergoing a rapid and ambitious healthcare transformation under the leadership of the custodian of the two holy mosques King Salman and HRH the Crown Prince Mohammed bin Salman. Vision 2030's Health Sector Transformation Program aims to create a world-class healthcare system that is efficient, patient-centric, and digitally advanced. BD is fully aligned with this vision. We are not just a medical technology provider but a healthcare solutions partner, committed to driving innovation, education, and collaboration. Our focus is on automation, digital health solutions, and value-based procurement, all of which contribute to making healthcare more efficient and accessible. Saudi Arabia's commitment to digitalization is unmatched. It is the leading nation in digitization, and we see this reflected in healthcare. BD is supporting this shift by introducing smart medication management systems and robotics to enhance pharmacy automation, reduce human error, and improve patient care. Q: BD has several initiatives in Saudi Arabia. Can you highlight some of the key programs and investments? A: Certainly. BD has evolved from a scientific office to a full commercial entity in Saudi Arabia, employing approximately 170 professionals and working alongside seven strategic distributors. Our commitment to Saudization is strong, and we continue to develop local talent in line with national workforce initiatives. One of our most exciting developments is the BD Training Center in Riyadh, which officially launched in April this year. This state-of-the-art facility will serve as a hub for healthcare professionals, providing hands-on training on BD's medical technologies, best practices, and clinical applications. It will also support technical training for engineers, ensuring seamless device maintenance and optimization. Recently, we also hosted our inaugural BD Healthcare Summit in Riyadh under the theme 'Embracing a Value Driven Future,' bringing together healthcare leaders to explore how AI, automation, and workforce empowerment can drive better outcomes in line with Saudi Arabia's Vision 2030. Additionally, BD has established a Regional Headquarters (RHQ) in Saudi Arabia, reinforcing our commitment to regional operations and market expansion. On the collaboration front, we have signed an MoU with STC to explore digital health solutions and are in discussions with multiplekey players to drive healthcare innovation. We also have an ongoing partnership with the Saudi Nursing Association, focusing on enhancing nursing education and clinical competency. Q: What are some of the new technologies BD is bringing to Saudi Arabia? A: Saudi Arabia is embracing cutting-edge healthcare solutions, and BD is at the forefront of this transformation. One of our key areas of focus is medication management systems and robotics, which optimize pharmacy automation, helping to ensure precise and efficient medication dispensing. These technologies not only enhance patient safety but also improve workflow efficiency in hospitals and pharmacies. We are also expanding our digital health solutions, aligning with Saudi Arabia's drive for smart healthcare systems. Our goal is to integrate automation, data-driven healthcare, and AI-supported medical technologies that elevate patient care standards. Q: Are there any partnerships or collaborations BD is working on in Saudi Arabia? A: Yes, partnerships are a key pillar of BD's strategy in Saudi Arabia. We have collaborated with Al Mujtamaa Pharmacy, making it the first digitally enabled pharmacy in Saudi Arabia using BD's advanced technology solutions. Additionally, BD has signed an MoU with STC, with further partnerships in discussion with Mobily and others toadvance digital healthcare and supply chain efficiency. A notable collaboration is our partnership with the Saudi Nursing Association, which focuses on continuous education and professional development for nurses across the Kingdom. This initiative underscores BD's commitment to capacity-building in the healthcare workforce. Q: What key trends do you see shaping the future of the Saudi healthcare sector, and how is BD contributing? A: The Saudi healthcare sector is moving toward value-based healthcare and value-based procurement models, where hospitals and institutions prioritize quality outcomes over mere cost efficiency. BD is actively engaging in this transition, particularly in laboratory solutions and diagnostics. Another major trend is digital transformation, where automation and data analytics are playing a pivotal role in improving healthcare services. BD is driving innovation in pharmacy automation, digital medication management, and clinical diagnostics to support this shift. Additionally, we see a strong push toward local manufacturing and public-private partnerships, and BD is keen to explore opportunities that align with these national priorities. Q: As a leader, what is your vision for BD's role in Saudi Arabia? A: My vision is clear: BD is here to stay and to lead. We are not just another healthcare technology provider; we are a long-term partner in Saudi Arabia's healthcare journey. Our role extends beyond revenue growth—we are committed to delivering value to patients, healthcare professionals, and the government. BD will continue to support innovation, drive medical education, and contribute to the national healthcare transformation through strategic partnerships and advanced solutions. A major part of this commitment is our focus on our Signature Programmes™, which align with the Kingdom's healthcare objectives. Through our investments, workforce development, and collaborations, BD is reinforcing its position as a trusted healthcare enabler in the Kingdom. Q: Any final thoughts or messages you'd like to share? A: I want to emphasize that BD's mission in Saudi Arabia is deeply rooted in improving patient care and healthcare efficiency. We are here not just to provide medical devices but to transform the healthcare experience, ensuring better outcomes for patients and healthcare professionals alike. Innovation is at the heart of BD, and we will continue to introduce cutting-edge technologies and best practices that align with the Kingdom's Vision 2030. Our training center, our partnerships, and our digital health initiatives all reflect BD's dedication to making a meaningful impact in Saudi Arabia's healthcare landscape. © Copyright 2022 The Saudi Gazette. All Rights Reserved. Provided by SyndiGate Media Inc. (

Web Release

12-06-2025

• Web Release

Dubai emerges as a regional hub for gene therapy breakthroughs: Medcare leads the way in transforming lives of children with rare genetic diseases

Dubai is rapidly establishing itself as a hub for cutting-edge gene therapy, with Medcare Royal Speciality Hospital Al Qusais being at the forefront of treating rare genetic disorders such as Spinal Muscular Atrophy (SMA) and Duchenne Muscular Dystrophy (DMD). With the hospital's proximity to the Dubai International Airport, a growing number of patients from Turkey, and other countries in the region and beyond are traveling to Dubai for life changing treatments. Medcare has been redefining excellence in the field of paediatric neurology and gene-based therapies, pioneering a new era of hope and healing for families affected by such debilitating conditions. Turkish families are increasingly turning to Medcare for SMA treatments, with incidence rates in Turkey significantly higher than the global average. The hospital's state-of-the-art facilities, international medical expertise, and holistic treatment model position it as a Centre of Excellence for gene disorders, not just in the UAE but across the MENA and the Asia-Pacific regions. SMA, a rare neurodegenerative condition, causes progressive muscle weakness and often proves fatal in infancy if left untreated. In Turkey, SMA affects 1 in every 6,000 births compared to 1 in 10,000 globally[i]. According to the Turkish health authorities, there are currently over 3,000 people living with SMA, and about 150 new cases are diagnosed each year. DMD, another severe neuromuscular disorder, affects over 4,000 genetically confirmed patients in Turkey[ii]. Under the leadership of Dr. Vivek Mundada, a British Board-certified Consultant Paediatric Neurologist at Medcare Royal Speciality Hospital has delivered remarkable outcomes in managing these complex genetic conditions. Unlike traditional therapies that require ongoing spinal injections, Medcare offers a one-time, potentially curative gene therapy that addresses the root cause of the condition, dramatically improving the quality of life and long-term health. Medcare is the first private healthcare provider outside the U.S.A. to successfully administer gene therapy for SMA in the MENA region, having delivered over 100 infusions to date at Medcare Women & Children Hospital. 'Dubai is becoming a center of medical innovation, and Medcare is proud to be leading that movement, especially in the field of rare genetic diseases,' said Dr. Vivek Mundada, Consultant Paediatric Neurologist at Medcare Royal Speciality Hospital. 'Through our comprehensive, patient-centered care model, we are transforming outcomes for children who previously had limited treatment options.' Medcare's approach goes beyond clinical excellence. Patients benefit from a multidisciplinary team that includes experts in neurology, pulmonology, orthopaedics, rehabilitation, and genetic counselling. The hospital also provides continuous follow-up care for international patients after they return home. Turkish families have already seen outstanding results. One such story is that of Mirha, diagnosed with SMA just nine days after she was born. In 2024, she underwent gene therapy at Medcare and is now thriving without the need for breathing or feeding support. Similarly, Elif Bade who was treated in March 2024 when she was just 2 years old, has shown remarkable progress following her gene therapy at Medcare. The parents of Mirha remarked, 'We cannot express enough gratitude to Dr. Mundada and the Medcare team. Thanks to the expert and compassionate care in Dubai, our daughter has been given a new lease on life.' Aligned with the UAE's vision to be a global hub for medical innovation and excellence, Medcare continues to invest in infrastructure, talent, and technology to offer best-in-class care. The newly launched rare disease unit at Medcare Royal Speciality Hospital in Dubai offers AI-powered diagnostics, robotic surgery, and advanced quaternary care, reinforcing its leadership in rare disease management. As part of Aster DM Healthcare, Medcare is committed to expanding access to advanced medical care for international patients, while contributing to the UAE's growing medical tourism sector, where families seek top-tier, cost-effective care without long wait times, especially for critical and time-sensitive conditions like the rare genetic disorders. [i] Turkey vs. Zolgensma: the battle over a $2.1 million drug – SWI [ii] About Duchenne Muscular Dystrophy – DMD Aileleri (Turkey)

Arabian Post

11-06-2025

• Arabian Post

Breakthrough Reveals Tylenol Blocks Pain at Its Source

A landmark study from the Hebrew University of Jerusalem challenges long-held beliefs about acetaminophen's mode of action, showing that its metabolite, AM404, halts pain signals in peripheral nerves by inhibiting specific sodium channels. This discovery, published in PNAS on 10 June 2025, marks a pivotal shift in pain management science. Historically, acetaminophen was thought to work primarily in the brain and spinal cord. The new research uncovers a peripheral mechanism: AM404 is generated in pain-sensing nerve endings and blocks voltage-gated sodium channels — specifically NaV1.7 and NaV1.8 — preventing pain signals from ever firing. The study was led by Professor Alexander Binshtok and Professor Avi Priel, combining expertise from the Faculty of Medicine and School of Pharmacy. Their team demonstrated that AM404 is synthesised locally in nociceptors and directly inhibits sodium currents, significantly reducing pain behaviours in both normal and inflamed rat models. ADVERTISEMENT This peripheral action mirrors the effect of local anaesthetics but targets only the nerves responsible for pain perception. As a result, AM404-based interventions could preserve motor and sensory functions, avoiding numbness or weakness commonly associated with traditional local anaesthetics. Prof. Binshtok stated, 'This is the first time we've shown that AM404 works directly on the nerves outside the brain. It changes our entire understanding of how acetaminophen fights pain'. Prof. Priel added that exploiting AM404's selectivity could lead to safer, more precise analgesics that bypass the side effects of existing medications. Published on 10 June 2025, the paper titled 'The analgesic paracetamol metabolite AM404 acts peripherally to directly inhibit sodium channels' identifies the compound's mechanism as state-dependent binding to the local anaesthetic site on NaV1.7 and NaV1.8 channels. These findings correct the incomplete understanding of acetaminophen as primarily a central nervous system agent and highlight a dual mechanism involving both central and peripheral pathways. Other experts in neuroscience are welcoming the breakthrough. Commentary in Medical Xpress noted that this 'ends a longstanding mystery' about how acetaminophen relieves pain. IFL Science emphasises the therapeutic promise: AM404's ability to selectively silence pain neurons could inspire local anaesthetics without typical side effects. From a pharmacological perspective, this discovery aligns with earlier theories by researchers like Stephen Waxman, who posited that peripheral sodium channels are viable targets for analgesia. NaV1.7 and NaV1.8 are central to pain signalling in peripheral neurons, a fact that has spurred generations of drug discovery efforts. Beyond academic significance, this insight opens a new paradigm for drug development. AM404's specific action suggests that chemists could design molecules that mimic or enhance its peripheral blocking properties, potentially offering pain relief without impairing motor function or causing dependency. The clinical implications are substantial. Opioids and traditional local anaesthetics carry risks of addiction, motor impairment, and systemic side effects. AM404-inspired drugs could provide non-addictive, nerve-targeted alternatives with fewer adverse effects, particularly in postoperative and chronic pain management. Next steps centre on translating these findings into human studies. Researchers must investigate whether AM404 concentrations in human peripheral tissues reach effective levels and evaluate long-term safety, metabolism, and efficacy across diverse patient populations. As Prof. Binshtok and Prof. Priel note, the journey has begun but much work remains to assess clinical potential. The discovery adds to a growing trend of re-evaluating old medications with modern techniques, uncovering their hidden benefits. It comes one month after Indiana University researchers pointed to acetaminophen's influence on endocannabinoid metabolism — another central mechanism — suggesting that the drug's effects may be multifaceted.